Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Keppra® is the first and only newer anti-epileptic drug approved in Europe for the treatment of myoclonic seizures in JME.
